title: Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country.
abstract: Tyrosine Kinase inhibitors (TKIs) have dramatically changed the prospects for patients with chronic myeloid leukemia (CML); however, information on CML and response to TKIs from Asia are limited, particularly from West Asia, including Iraq. To address the latter issue we evaluated and monitored a cohort of 108 Iraqi patients diagnosed as chronic phase-CML, enrolled in a government-sponsored national program. The patients were all treated initially by imatinib mesylate. Ninety-two percent of patients had a complete hematological response, 38% had a major molecular response, while 79% had a major cytogenetic response after a median follow-up of 35.7 months. The 3-year Event-Free, Progression-Free, and Overall survival rates were 79.6, 87 and 98.1%, respectively. A total of 26 patients (24.1%) were shifted to an alternative TKI (Nilotinib). After one year of therapy in seventeen of the latter patients, 24% had major molecular response. In conclusion, our results compare favorably with those reported from the West and some Asian countries, and have demonstrated the importance of molecular as well as cytogenetic monitoring, and confirmed the relative success of the national CML program in our country.
authors.affiliation: Department of Hematology, Nana Kelly Hospital, Erbil, Iraq, ali6764@yahoo.com.
authors.forename: Mohammed Dhahir
authors.initials: MD
authors.lastname: Ali
authors.forename: Ameer I
authors.initials: AI
authors.lastname: Badi
authors.forename: Shaima S M
authors.initials: SS
authors.lastname: Al-Zebari
authors.forename: Nasir A S
authors.initials: NA
authors.lastname: Al-Allawi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007493:Iraq; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib
references.citation: Int J Hematol. 2009 Jan;89(1):14-23
references.pmid: 19101781
references.citation: Cancer. 2008 May 15;112(10):2112-8
references.pmid: 18348294
references.citation: Blood. 2009 Jun 18;113(25):6315-21
references.pmid: 19369233
references.citation: Cancer. 2003 Dec 15;98(12):2636-42
references.pmid: 14669283
references.citation: Mediterr J Hematol Infect Dis. 2014 Jan 02;6(1):e2014005
references.pmid: 24455114
references.citation: N Engl J Med. 2002 Feb 28;346(9):645-52
references.pmid: 11870241
references.citation: Blood. 2011 Jul 21;118(3):686-92
references.pmid: 21536864
references.citation: Blood. 2007 Oct 15;110(8):2828-37
references.pmid: 17626839
references.citation: Cancer. 2005 Apr 15;103(8):1659-69
references.pmid: 15747376
references.citation: Blood. 2012 May 10;119(19):4524-6
references.pmid: 22431574
references.citation: Indian J Hematol Blood Transfus. 2012 Jun;28(2):82-8
references.pmid: 23730014
references.citation: J Natl Cancer Inst. 1998 Jun 3;90(11):850-8
references.pmid: 9625174
references.citation: Pediatr Blood Cancer. 2011 Jul 15;57(1):56-62
references.pmid: 21465636
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6041-51
references.pmid: 19884523
references.citation: Cancer. 2006 Mar 15;106(6):1306-15
references.pmid: 16463391
references.citation: Blood. 2002 Mar 15;99(6):1928-37
references.pmid: 11877262
references.citation: Blood. 2011 Jan 27;117(4):1141-5
references.pmid: 21098399
references.citation: Blood. 2013 Aug 8;122(6):872-84
references.pmid: 23803709
references.citation: Ann Hematol. 2011 Jan;90(1):41-6
references.pmid: 20668855
references.citation: Eur J Haematol. 2011 Aug;87(2):157-68
references.pmid: 21535160
references.citation: J Assoc Physicians India. 2005 Apr;53:291-5
references.pmid: 15987013
references.citation: Hematology Am Soc Hematol Educ Program. 2003;:132-52
references.pmid: 14633780
references.citation: Haematologica. 2010 Aug;95(8):1317-24
references.pmid: 20220063
references.citation: Turk J Haematol. 2013 Dec;30(4):387-93
references.pmid: 24385829
references.citation: N Engl J Med. 2010 Jun 17;362(24):2251-9
references.pmid: 20525993
references.citation: Mediterr J Hematol Infect Dis. 2014 Jan 02;6(1):e2014007
references.pmid: 24455116
references.citation: Blood. 1984 Apr;63(4):789-99
references.pmid: 6584184
references.citation: Blood. 2003 May 15;101(10):3794-800
references.pmid: 12560227
references.citation: Blood. 2011 May 26;117(21):5591-9
references.pmid: 21450900
references.citation: Hematol Oncol Clin North Am. 2004 Jun;18(3):569-84, viii
references.pmid: 15271393